Dr. Rory O’Connor qualified in Medicine from the University of Liverpool in 1978 and trained in Cardiology and General Medicine before joining the pharmaceutical industry in 1989. He has been with Pfizer for 19 years, originally with Global Research ＆ Development in Sandwich UK, working in neuroscience development with responsibility for antipsychotic and neuroprotective agents. In 1996 he moved to Pfizer HQ in New York as Medical Director Neuroscience, leading the strategic development and launch of a novel antipsychotic, including direction of the associated global phase IIIb/IV clinical program. In 2000 he assumed responsibility for Medical Affairs for Pfizer’s European operations, based in New York. In 2009 he returned to Europe from New York as Vice-President, Medical Affairs, Primary Care Business Unit for Europe. In January 2014 he was appointed Senior Vice-President, Head of Global Medical Affairs, Global Innovative Pharma Business.
He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK).